- About ExoGenis
We unlock the power of biologics — without the burden of injections
We are a biotechnology delivery platform operating at the intersection of biologic delivery, clinical aesthetics, and dermatology.
- What we do
ExoGenis provides a biologic-compatible, non-injectable delivery layer that enables predictable, repeatable placement of fragile biologics into viable skin — filling the gap between topical products and injectable treatments.
our mission
To enable precise, non-injectable delivery of biologics into skin by bridging the gap between topical treatments and injectable procedures.
our vision
A future where biologic therapies can be delivered locally and precisely into skin, without injections and with reduced clinical burden.
- our team
Leadership and Scientific advisors
- our journey
Milestones
Our technology is validated through rigorous scientific partnerships with leading research institutions.
2025
2026
01
Company founded
ExoGenis established to develop a biologic-compatible microneedle delivery platform for fragile biologics.
02
Initial research & development
Core dissolvable microneedle architecture and coating approach developed.
03
Validated prototype
Technical validation of delivery performance, stability, and controlled depth completed in Denmark.
04
Clinical pilots
Launch with select partner clinics in Europe and the UK for real-world validation.
- Partnerships
Scientific collaborations
Our technology is validated through rigorous scientific partnerships with leading research institutions.

.webp)
micro‑coating partner
.webp)
.webp)
.webp)
Join us in shaping the future
Whether you're a potential partner, investor, or simply curious about our technology, we'd love to hear from you.
.webp)

.webp)
